Interestingly, a correlation between exosomes and effectiveness of monoclonal antibody-based therapy has already been found in breast cancer: exosomes secreted by HER2-overexpressing breast carcinoma cells express full-length HER2 molecules on their surface, which bind and sequester Trastuzumab (a therapeutic monoclonal antibody) and lower its therapeutic efficacy [33]. Here, ERBB2 is linked to breast carcinoma.